Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines

December 14, 2023

https://www.globenewswire.com/news-release/2023/12/14/2796727/0/en/Cullinan-Oncology-Announces-First-Patient-Dosed-in-Phase-1-Trial-Evaluating-CLN-617-a-Novel-Fusion-Protein-Uniquely-Harnessing-Both-IL-2-and-IL-12-Cytokines.html

CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq:CGEM), a biopharmaceutical company focused on modality-agnostic, targeted oncology therapies, today announced that the first patient has been dosed with CLN-617 in a Phase 1 clinical trial. This is a first-in-human, multi-center, open label study designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of CLN-617 alone and in combination with pembrolizumab, a programmed death receptor-1 (PD-1) targeted checkpoint inhibitor, in patients with advanced solid tumors.

Read more at globenewswire.com

Related news for (CGEM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.